PAST SPEAKERS
Laura Matz
Chief Science & Technology Officer
Merck
Richard Bickerton
Chief System
Scientist Exscientia
Chris Gibson
CEO
Recursion
Fred Manby
CEO
Iambic Therapeutics
Craig Johnstone
Chief Operating Officer
Evotec
Ashwini Ghogare
Head of AI and Automation for Drug Discovery
Merck
Leaders shaping the future of drug discovery and beyond
KEYNOTES & ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King
Where Visionary Leadership Meets Transformative Innovation
The Drug Discovery to Development Leaders summit gathers a global community of C-suite executives, pioneering scientists, and forward-thinking strategists who are at the forefront of transforming the future of pharma. This isn’t just another industry event—it’s a powerful catalyst for change. Tailored for leaders eager to break down silos and drive next-generation innovation, our program dives into the future of drug discovery with a focus on emerging technologies.
Join us to explore how macrocyclic drug candidates, small molecules, generative AI, machine learning, and Explainable AI (XAI) are revolutionising early-stage research, uncovering novel drug candidates, and reshaping the most complex phase of development: Phase 3 clinical trials. XAI, with its ability to provide transparency and build trust in AI-driven decisions, is playing a pivotal role in accelerating the journey from discovery to approval. Together, we’ll chart a bold path forward—empowering CROs, IRO’s and industry leaders to bring life-saving therapies to patients faster, smarter, and more efficiently than ever before.
Werngard Czechtizky
Executive Director Head Medicinal Chemistry, Respiratory and Immunology at AstraZeneca
CONFIRMED SPEAKERS 2025
2025 PROGRAMME SNAPSHOT
KEY TOPICS
-
Revolutionising healthcare through digital innovation
-
AI-Enhanced Clinical Trials
-
Explainable AI (XAI) in Drug Discovery enhances the interpretability, transparency, and trustworthiness of AI tools.
-
AI in biomarker discovery and personalised medicine
-
A novel and differentiated approach to targeted protein degradation
-
Integration of Quantum computing in drug discovery
VENDOR FOCUS
-
Biomarker discovery and personalised Medicine
-
Explainable AI (XAI)
-
Generative AI for drug design
-
AI-Accelerated clinical trials
-
AI-Driven drug repurposing
-
Integration of AI with genomics and bioinformatics
-
Advancements in protein structure prediction
-
Advances in Gene Editing technologies
WHY & MISSION
For over 16 years, we’ve walked alongside the pioneers—the CXOs, thought leaders, and bold thinkers pushing the boundaries of drug discovery. What brings us together, beyond titles and disciplines, is a deeper calling: the drive to make a real difference. We’re united by purpose, fueled by possibility, and grounded in one undeniable truth—patients deserve better. And that’s why we show up - for the patients. And ‘For the patients, we must do better’.
WHY ATTEND
Engage in thought-provoking discussions on challenges and opportunities facing the drug discovery industry
Revolutionize R&D through AI & Machine Learning
In-Person only attendance of up to 200 decision-makers
Maximise your time by taking part in our exclusive pre-qualified one-to-one networking service
Hear exclusively from renowned leaders presenting on challenges when leveraging digital technologies, artificial intelligence, and machine learning in your innovation cycle
Leveraging AI to unblock drug discovery, drug repurposing and target validation
Explore the latest advancements, breakthroughs, and innovative approaches in the quest for new drugs and therapies
Uncover novel therapeutics targets, drug candidates, and innovative approaches that can drive the development of life-changing treatments
Journey of a CXO - witness in person The Why? The journey and destination of some of the most inspirational CXO’s in the industry
"Our mission remains the same - deliver accurate, reliable and compelling content that equates to business partnerships and collaborations that impact better patients outcomes."
INNOVATION SPOTLIGHT
-
Revolutionising healthcare through Digital Innovation by Merck
-
Case-Studies in AI-Driven Drug Discovery by Insilico Medicine
-
Meeting Pharma Challenges Head-on with AI Innovation by Aion Labs
-
AI/ML and Drug Discovery: ab in silico ad humanum by Novartis
WHY ATTEND
-
In-person only
-
Closed door
-
Boutique
-
Pre qualified and invited audience
-
Curated meetings
-
Fireside chats
-
Evaluate partnerships, ROI, and IP potential
-
Validate science, novel MOAs, ROI on early R&D investments
-
Competitive advantage, strategic alignment, pilot opportunities
WHO ATTENDS
-
Chief Scientific Officer (CSO)
-
Head of R&D
-
Head of Drug Discovery
-
Translational Medicine
-
VP/Director of Computational Biology - Bioinformatics - Data Science
-
Head of Innovation - AI Strategy - Outsourcing - Integration - Digital Transformation
-
Business Development - Corporate Strategy Teams
Type of Job Titles Attending:
-
CEO
-
CSO
-
CTO
-
CIO
-
EVP/SVP/VP
-
Director
Type of Companies Attending:
-
Pharmaceutical Organizations
-
Pharma and Research Institutions
-
Contract Development and Manufacturing Organizations
-
Government and Regulatory Agencies
-
Biotech Companies
-
Drug Discovery Solution Providers
-
Digital health and software providers
-
Logistics and supply chain companies
How CAN WE really use AI to advance drug discovery?
An invite only assembly of up to 200 leaders committed in making an impact.
It's people, their stories and this momentum that inspires purpose
THE NUMBERS
200+
Up to 200 decision-makers in person. Previous attendee demographics include 50% EMEA, 30% America and 20% ROW
20%
20% best-of-breed vendors supporting the drug discovery industry
06
Journey of CXO presentations. Six insightful, powerful and inspirational talks from CXOs in the industry
02
Exclusive in-person networking, over 2 days in Barcelona 2025
7+
Pre-scheduled and pre-qualified one-to-one meetings with delegates who can either influence or make a decision
90%
Over 90% of our attendance provided positive feedback. Please click here to see what our delegation has to say
PREVIOUS SPEAKERS
